Outcomes in COVID-19 atovaquone studies

All studies   Mortality   Hospitalization   Serious outcomes   RCTs   RCT mortality   Peer-reviewed   All outcomes  
0 0.5 1 1.5+ All studies -39% 1 60 Improvement, Studies, Patients Relative Risk Mortality -39% 1 60 Hospitalization 16% 1 60 RCTs -39% 1 60 Late -39% 1 60 Atovaquone for COVID-19 c19early.org November 2025 Favorsatovaquone Favorscontrol
0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Jain (DB RCT) -39% 1.39 [0.31-6.26] death 6/41 2/19 Improvement, RR [CI] Treatment Control Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.68 Late treatment -39% 1.39 [0.31-6.26] 6/41 2/19 39% higher risk All studies -39% 1.39 [0.31-6.26] 6/41 2/19 39% higher risk 1 atovaquone COVID-19 study c19early.org November 2025 Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.68 Effect extraction pre-specified(most serious outcome) Favors atovaquone Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Jain (DB RCT) -39% 1.39 [0.31-6.26] 6/41 2/19 Improvement, RR [CI] Treatment Control Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.68 Late treatment -39% 1.39 [0.31-6.26] 6/41 2/19 39% higher risk All studies -39% 1.39 [0.31-6.26] 6/41 2/19 39% higher risk 1 atovaquone COVID-19 mortality result c19early.org November 2025 Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.68 Favors atovaquone Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Jain (DB RCT) 16% 0.84 [0.70-1.01] hosp. time 41 (n) 19 (n) Improvement, RR [CI] Treatment Control Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.069 Late treatment 16% 0.84 [0.70-1.01] 41 (n) 19 (n) 16% lower risk All studies 16% 0.84 [0.70-1.01] 41 (n) 19 (n) 16% lower risk 1 atovaquone COVID-19 hospitalization result c19early.org November 2025 Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.069 Favors atovaquone Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Jain (DB RCT) -39% 1.39 [0.31-6.26] death 6/41 2/19 Improvement, RR [CI] Treatment Control Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.68 Late treatment -39% 1.39 [0.31-6.26] 6/41 2/19 39% higher risk All studies -39% 1.39 [0.31-6.26] 6/41 2/19 39% higher risk 1 atovaquone COVID-19 serious outcome c19early.org November 2025 Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.68 Effect extraction pre-specified(most serious outcome) Favors atovaquone Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Jain (DB RCT) -39% 1.39 [0.31-6.26] death 6/41 2/19 Improvement, RR [CI] Treatment Control Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.68 Late treatment -39% 1.39 [0.31-6.26] 6/41 2/19 39% higher risk All studies -39% 1.39 [0.31-6.26] 6/41 2/19 39% higher risk 1 atovaquone COVID-19 Randomized Controlled Trial c19early.org November 2025 Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.68 Effect extraction pre-specified(most serious outcome) Favors atovaquone Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Jain (DB RCT) -39% 1.39 [0.31-6.26] 6/41 2/19 Improvement, RR [CI] Treatment Control Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.68 Late treatment -39% 1.39 [0.31-6.26] 6/41 2/19 39% higher risk All studies -39% 1.39 [0.31-6.26] 6/41 2/19 39% higher risk 1 atovaquone COVID-19 RCT mortality result c19early.org November 2025 Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.68 Favors atovaquone Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Jain (DB RCT) -39% 1.39 [0.31-6.26] death 6/41 2/19 Improvement, RR [CI] Treatment Control Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.68 Late treatment -39% 1.39 [0.31-6.26] 6/41 2/19 39% higher risk All studies -39% 1.39 [0.31-6.26] 6/41 2/19 39% higher risk 1 atovaquone COVID-19 peer reviewed studies c19early.org November 2025 Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.68 Effect extraction pre-specified(most serious outcome) Favors atovaquone Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Jain (DB RCT) -39% 1.39 [0.31-6.26] death 6/41 2/19 Improvement, RR [CI] Treatment Control Jain (DB RCT) 20% 0.80 [0.42-1.52] no improv. 15/40 8/17 Jain (DB RCT) 15% 0.85 [0.71-1.02] no improv. 33/41 18/19 Jain (DB RCT) 16% 0.84 [0.70-1.01] hosp. time 41 (n) 19 (n) Atovaquone COVID-19 outcomes c19early.org November 2025 Favors atovaquone Favors control